Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

NCT04686643 is registered in ClinicalTrials.gov with Ahn-Gook Pharmaceuticals Co.,Ltd as lead sponsor.

NCT NCT04686643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04686643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
Lead sponsor
Ahn-Gook Pharmaceuticals Co.,Ltd
Phase
Phase 3
Overall status
Unknown status
Start date
February 1, 2021
Completion date
May 1, 2022
Enrollment
306 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension